Inovio Pharmaceuticals
98 hedge funds and large institutions have $153M invested in Inovio Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 16 closing their positions.
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
19% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 26
4% more funds holding
Funds holding: 94 → 98 (+4)
0.17% more ownership
Funds ownership: 2.43% → 2.59% (+0.17%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less call options, than puts
Call options by funds: $1.35M | Put options by funds: $1.4M
5% less capital invested
Capital invested by funds: $161M → $153M (-$7.74M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$9.33M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.72M |
| 3 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
+$1.15M |
| 4 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
+$738K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$706K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.43M |
| 2 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$2.34M |
| 3 |
Goldman Sachs
New York
|
-$1.06M |
| 4 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$754K |
| 5 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
-$614K |
INO Hedge Fund Activity: Q1 2015 in Review
98 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2015, worth a combined $153M — down 4.8% from $161M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new INO positions and 16 closed out — a net gain of 4 holders — while 31 added to existing stakes and 26 trimmed.
The largest buyer was State Street, adding an estimated $9.33M. The largest seller was Guggenheim Capital, exiting entirely with an estimated $2.43M sold.
- 98 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2015, up from 94 in Q4 2014.
- Funds reported $153M of Inovio Pharmaceuticals stock for Q1 2015, down 4.8% quarter-over-quarter.
- 20 funds opened new Inovio Pharmaceuticals positions in Q1 2015 and 16 closed out, a net change of +4 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2015 was State Street, an estimated $9.33M added.
- The largest Inovio Pharmaceuticals seller in Q1 2015 was Guggenheim Capital, an estimated $2.43M sold.
Based on aggregated 13F filings for Q1 2015.